MedTrace Logo

Spironolactone for Paroxysmal Atrial Fibrillation

NCT00689598 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-06-05

No results posted yet for this study

Summary

To determine whether or not spironolactone can prevent or delay the occurrence of atrial fibrillation.

Conditions

Interventions

DRUG

Spironolactone

25 mg po qd 25 mg po bid

DRUG

Placebo

Spironolactone 25 mg po qd

Sponsors & Collaborators

  • Taichung Veterans General Hospital

    lead OTHER

Principal Investigators

  • Tsu-Juey Wu, M.D. · TCVGH

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00689598 on ClinicalTrials.gov